http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2508900-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d103ce513d19f5f6a3d83fbe75b7ad39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f557e4a9244e2362466d42f31322efdc
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
filingDate 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8dbd69b8e4fbbd4a9a97e7555b9cbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a756df3d06a5ff73d66f8cd3dae0da7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_838d7e4b62ce67807038525f027a0dd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7def622a2ddd4509629689eea3d0d7a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_195d1eee165c14a26319db8dea827bd5
publicationDate 2014-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2508900-C1
titleOfInvention Method for assessing blood flow state in healthy individuals with cardiovascular risk factors and in cardiovascular patients
abstract FIELD: medicine. n SUBSTANCE: invention refers to medicine, specifically cardiology. A contour analysis of a pulse wave recorded by photoplethysmography is conducted in individuals being tested. A rigidity index is used to assess the state of a greater vascular wall. If the rigidity index is more than 8 m/s, the structural changes of the great vascular wall (Sk+) are recorded, and the rigidity index less than 8 m/s shows no structural changes of the greater vessels (Sk-). That is combined with a computer-assisted capillaroscopy of a periungual bed and dorsal finger skin. A capillary remodelling more than 1.33, rest capillary network density more than 45 drop/mm 2 , as well as capillary network density after a venous occlusion test more than 56 drop/mm 2 , show no structural changes of the microvessels (Sm-). If observing abnormal values of at least one parameter, the structural changes of the microvessels (Sm+) are stated. That is followed by an occlusion photoplethysmography to assess the functional changes of the greater vessels and microvasculature on the basis of a phase shift and an occlusion index. If the phase shift is less than 10 m/s, the functional disturbances of the greater vessels (Fk+), and the value more than 10 m/s shows no functional disturbances (Fk-). If the occlusion index is more than 1.8, the functional changes of the microvascular wall (Fm+) are stated, while the given value less than 1.8 shows no functional changes (Fm-). The structural-functional changes of the greater vessels, microvasculature and combinations thereof are detected to provide a basis to assess the blood flow state. A combination (Fk-Sk-; Fm-Sm-) show no disturbances of the blood flow considered as degree 0. The combination (Fk-Sk-; Fm+Sm-), (Fk+Sk-; Fm+Sm-), (Fk+Sk-; Fm-Sm-) provides considering the degree 1 blood flow involvement. The combinations (Fk-Sk+; Fm-Sm-) and (Fk+Sk+; Fm-Sm-) enables assessing the degree 2 involvement. The combinations (Fk-Sk+; Fm+Sm-) provide the degree 3 involvement. The combinations (Fk-Sk-; Fm-Sm-) and (Fk-Sk-; Fm+Sm+) provide stating the degree 4 involvement. The degree 5 blood flow involvement is shown by the combinations (Fk+Sk-; Fm-Sm+), (Fk-Sk+; Fm-Sm+), (Fk+Sk+; Fm-Sm+), (Fk+Sk-; Fm+Sm+), (Fk-Sk+; Fm+Sm+), (Fk+Sk+; Fm+Sm+), (Fk+Sk+; Fm+Sm-). n EFFECT: method enables the integrated assessment of the blood flow state at different levels to determine a version of the vascular wall changes and a degree of the blood flow involvement; they are highly specific, highly reproducible, non-invasive and have no contraindications, which creates an opportunity for more effective primary prevention of CVD. n 3 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2585163-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2718303-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2646659-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2580970-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2731414-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2595483-C2
priorityDate 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25201348
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451646703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555446
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485969
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5388961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107807
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4485
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4171
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536333
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2405
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565407
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493554
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID38945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533897
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503133

Total number of triples: 44.